

Detta informationsblad till obligationsinnehavarna är endast utformat på engelska.

Stockholm, April, 1st, 2019

To the bondholders in:

ISIN: SE0007953989 – Moberg Pharma AB (publ) maximum SEK 600,000,000 Senior Unsecured Bonds 2016/2021

NOTICE OF EARLY REDEMPTION

This notice of early redemption has been sent on April 1st, 2019 to Holders directly registered as of March 29th, 2019 in the debt register (Sw. *skuldbok*) kept by the CSD. If you are an authorised nominee under the Swedish Central Securities Depositories and Financial Instruments Accounts Act or if you otherwise are holding Bonds on behalf of someone else on a securities account, please forward this notice to the holder you represent as soon as possible.

Reference is made to the terms and conditions of the above mentioned bond issue (with an aggregate amount outstanding of SEK 600,000,000) (the “**Bonds**”) issued by Moberg Pharma AB (publ) (the “**Issuer**” or “**Moberg Pharma**”) initially on January 29th, 2016 (the “**Terms and Conditions**”). All capitalised terms used herein and not otherwise defined in this notice shall have the meanings assigned to them in the Terms and Conditions.

Moberg Pharma hereby gives notice to all Holders of Moberg Pharma’s outstanding Bonds of exercise of its option for early redemption of the Bonds in full in accordance with section 10 of the Terms and Conditions. The early redemption date is set to April 29th, 2019 (the “**Early Redemption Date**”). As set out in the Terms and Conditions, all Bonds will be redeemed at 104.00 per cent. of the Nominal Amount (*i.e.* SEK 1,040,000 per Bond). Any accrued and unpaid interest will also be paid in respect of the Bonds in accordance with the Terms and Conditions.

The redemption amount, together with accrued and unpaid interest up to and including the Early Redemption Date, will be paid to each person who is registered as owner of Bonds in the debt register maintained by Euroclear Sweden at end of business on April 18th, 2019. In connection with the redemption, the Bonds will be delisted from Nasdaq Stockholm.

This notice of early redemption is irrevocable and is governed by Swedish law. This notice is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Issuer.

For further information, please contact the Issuer at:

Peter Wolpert, CEO, phone: Sweden: +46 707 35 7135, US: +1 908 432 2203,

e-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO, phone: +46 707 66 6030, e-mail: anna.ljung@mobergpharma.se

MOBERG PHARMA AB (PUBL)